NATIONAL BLOOD AUTHORITY
AUSTRALIA

Governance

You can't dispense with dispensing!

Jo Cameron
Program Director

National Blood Authority
Canberra, Australia

NICE Tasmania - 2018

NATIONAL BLOOD AUTHORITY
AUSTRALIA

Australian usage statistics

Source: National Report on the Issue and Use of Immunoglobulin 2016-17, National Blood Authority

NATIONAL BLOOD AUTHORITY
AUSTRALIA

Ig Usage in Australia



NATIONAL BLOOD AUTHORITY
AUSTRALIA

Ig Governance Program



Ig Governance Program



NATIONAL BLOOD AUTHORITY
AUSTRALIA

Criteria for Use

Criteria for the clinical use of
immunoglobulin
in Australia

Version 3



BLOODSTAR Processes and Roles

System Role

Prescriber

Authoriser

Nurse

Dispenser
(via BloodNet)

Blood Service
Customer Service &
Order Fulfilment





The dispenser will only issue immunoglobulin against requirements authorised in BloodSTAR. All dispenses of immunoglobulin should be recorded in BloodNet by the dispenser.

NATIONAL BLOOD AUTHORITY
AUSTRALIA

The National Policy - Dispensers

Dispensing product for authorised patients only

The responsibilities for dispensing of product include:

- reviewing the hospital/facility blood product orders from a prescriber or from the ward (this may be in the form of the dispense request submitted through BloodSTAR or another process recognised within the hospital/health service governance arrangements) and only dispensing approved product and dose in accordance with current patient authorisations confirmed in BloodSTAR
- when dispensing SCIg product, dispensing no more product than is required for two months' treatment directly to authorised patients or their parent/carer/guardian
- recording the dispensing information (authorised patients or otherwise) in relevant information systems to ensure traceability of product dispensed to patients in case of product recall
- reconciling dispense records with authorisations to identify, investigate and correct anomalies.

BLOODNET

TRAINING

Change facility | Jo CAMERON (NBA) | Session expires in 19:01

View authorisation

TEST, Ted

01/01/2000 18 year old, Male Edit patient details

Facility identifiers

Edit

Authorisation details

Authorisation status: Active

Authorisation number: JK95923B

Approved date: 13/02/2018

Authorisation end date: 01/04/2019

Continuing supply is conditional on a review being conducted prior to this date

Treating specialist: Miss Claire MATHESON
Support Officer
Royal Perth Hospital

Medical condition: Myasthenia gravis (MG)

Specific condition: Myasthenia gravis

Indication: As maintenance therapy for moderate to severe MG when other treatments have been ineffective or caused intolerable side effects.

Regimen: Maintenance Dose INTRAGAM 10 32.50 grams every 6 weeks. (Intravenous)

Weight: 70.00 kg

Treating facility: Royal Perth Hospital

Administering facility: Royal Perth Hospital

Dispensing facility: PathWest Laboratory Medicine WA - Royal Perth Hospital Edit

Last dispensed date: 19/09/2018

BLOODNET

Treatment plan

This treatment plan does not constitute a prescription for immunoglobulin product.

dispensed quantity is less than approved quantity
dispensed quantity is greater than approved quantity

Planned Date	Dose type	Dose	Status	Requested	Expected infusion date	Date dispensed	Quantity dispensed	Action
03/09/2018	Maintenance Dose	INTRAGAM 10 32.50 g	Partially Dispensed		03/09/2018	10/08/2018	5 g of 32.5 g	View/Edit
15/10/2018	Maintenance Dose	INTRAGAM 10 32.50 g	Dispensed		13/09/2018	13/09/2018	32.5 g of 32.5 g	View/Edit Dispense Return to Stock
25/10/2018	Maintenance Dose	INTRAGAM 10 32.50 g	Planned	✔	25/10/2018			View/Edit Dispense
06/12/2018	Maintenance Dose	INTRAGAM 10 32.50 g	Planned					View
17/01/2019	Maintenance Dose	INTRAGAM 10 32.50 g	Planned					View
28/02/2019	Maintenance Dose	INTRAGAM 10 32.50 g	Planned					View

Authorisation Details | Record Review | Authorisation History | Assessment Amendment History

Authorisation Number

Approval Date 13-Feb-2018

Medical Condition Myasthenia gravis (MG)

Specific Condition Myasthenia gravis

Indication As maintenance therapy for moderate to severe MG when other treatments have been ineffective or caused intolerable side effects.

Treating Specialist Miss Claire MATHESON
Support Officer - Royal Perth Hospital

Regimen

Dose Type	Dose	Infusion Method	Action
Maintenance Dose	INTRAGAM 10 - 32.50 grams every 6 weeks.	Intravenous	+ Request Change

+ Request Additional Induction Dose

Authorisation End Date 01-Apr-2019 Continuing supply is conditional on a review being conducted prior to this date.

Treating Facility Royal Perth Hospital

Administering Facility Royal Perth Hospital

Dispensing Facility PathWest Laboratory Medicine WA - Royal Perth Hospital

Last Dispensed Date 19-Sep-2018

Print | Edit

Treatment Plan

This treatment plan does not constitute a prescription for immunoglobulin products.

Planned Date	Dose Type	Dose	Status	Requested	Expected Infusion Date	Date Dispensed	Dispensed
03-Sep-2018	Maintenance Dose	INTRAGAM 10 - 32.50 g	Partially Dispensed		03-Sep-2018	10-Aug-2018	5.00g of 32.50g
15-Oct-2018	Maintenance Dose	INTRAGAM 10 - 32.50 g	Dispensed		13-Sep-2018	13-Sep-2018	32.50g of 32.50g
25-Oct-2018	Maintenance Dose	INTRAGAM 10 - 32.50 g	Planned	✔	25-Oct-2018		0.00g of 32.50g
06-Dec-2018	Maintenance Dose	INTRAGAM 10 - 32.50 g	Planned				
17-Jan-2019	Maintenance Dose	INTRAGAM 10 - 32.50 g	Planned				
28-Feb-2019	Maintenance Dose	INTRAGAM 10 - 32.50 g	Planned				

NATIONAL BLOOD AUTHORITY
AUSTRALIA

Q&A

Thank you

Jo Cameron
Director, Immunoglobulin Governance Program

National Blood Authority, Canberra Australia
iggovernance@blood.gov.au

www.blood.gov.au